COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Low Dose Promethazine for Postoperative Nausea and Vomiting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01159548
Recruitment Status : Terminated (Population of interest was no longer available)
First Posted : July 9, 2010
Last Update Posted : July 27, 2011
Information provided by:
Women's College Hospital

Brief Summary:

There has been an increase in ambulatory surgical procedures performed across Canada; ambulatory procedures account for almost 70% of all surgeries. Postoperative nausea and vomiting (PONV) and pain are the most frequently reported adverse events by patients prior to discharge after ambulatory surgery. The incidence can be as high as 70 to 80% in high-risk patients.

PONV is a cause of morbidity particularly in gynecological procedures and the incidence of patients experiencing PONV is as high as 58-75%. Apart from delayed recovery, the occurrence of PONV has been linked to gastric aspiration, psychological distress and wound dehiscence. The occurrence of PONV delays patient discharge and further more is a leading cause of unexpected admission after ambulatory anesthesia

Promethazine, is an antiemetic medication that has been widely used over the last 50 years, and although effective at reducing PONV, it tends to cause sedation. In this study, we are trying to determine if a smaller dose of promethazine, in addition to the standard treatment for post-surgical nausea and vomiting, will be more beneficial than the standard treatment on its own.

It is hypothesized that the use of low dose promethazine (3 mg) as part of a multimodal antiemetic regimen will be efficacious in preventing PONV without the sedative effects of promethazine.

Condition or disease Intervention/treatment Phase
Ambulatory Gynecological Laparoscopic Procedures Drug: Promethazine Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Study Start Date : July 2010
Estimated Primary Completion Date : July 2012
Estimated Study Completion Date : July 2012

Arm Intervention/treatment
No Intervention: Saline
Promethazine 6.25 mg Drug: Promethazine
Promethazine 3 mg Drug: Promethazine

Primary Outcome Measures :
  1. Absence of emetic episode for 24 h in the postoperative period

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Patient is between 18 - 60 yrs of age

2 Patient's health is graded as class I-III according to the American Society of Anesthesiologists physical status classification.

3. The patient has 2 or more of the following risk factors:

  • Female
  • Non-smoker
  • History of PONV/motion sickness
  • Use of post-operative opioids (current surgery)

    4. Undergoing ambulatory gynecological laparoscopic procedures of at least 30 minutes duration

Exclusion Criteria:

  • preexisting nausea, vomiting or retching, gastric outlet or intestinal obstruction
  • clinical evidence of a difficult airway
  • obesity (body mass index > 40 kg m-2)
  • scheduled to receive propofol for anesthesia maintenance
  • current pregnancy
  • psychiatric illness
  • clinically significant major organic disease
  • preoperative QTc interval > 440 ms on electrocardiogram
  • known hypersensitivity to promethazine, granisetron, ondansetron or other 5 HT3-receptor antagonists

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01159548

Layout table for location information
Canada, Ontario
Women's College Hospital
Toronto, Ontario, Canada, M5S 1B2
Sponsors and Collaborators
Women's College Hospital
Layout table for investigator information
Principal Investigator: Jean Kronberg, MD, PhD Women's College Hospital

Layout table for additonal information
Responsible Party: Dr. Jean Kronberg, Women's College Hospital Identifier: NCT01159548    
Other Study ID Numbers: 2009-0034B
First Posted: July 9, 2010    Key Record Dates
Last Update Posted: July 27, 2011
Last Verified: July 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatologic Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Allergic Agents
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Anesthetics, Local
Sensory System Agents
Peripheral Nervous System Agents
Autonomic Agents
Gastrointestinal Agents